AR017511A1 - ISOLATED POLINUCLEOTIDES THAT CODIFY LBPB OF NEISSERIA MENINGITIDIS, GUEST CELLS TRANSFORMED WITH RECOMBINANT EXPRESSION SYSTEM CAPAZDE TO PRODUCE LBPB POLYPEPTIDE IN BONES CELLS, SUCH CELLULES, BODY CELLS, BIRTHDAYS, BODIES - Google Patents
ISOLATED POLINUCLEOTIDES THAT CODIFY LBPB OF NEISSERIA MENINGITIDIS, GUEST CELLS TRANSFORMED WITH RECOMBINANT EXPRESSION SYSTEM CAPAZDE TO PRODUCE LBPB POLYPEPTIDE IN BONES CELLS, SUCH CELLULES, BODY CELLS, BIRTHDAYS, BODIESInfo
- Publication number
- AR017511A1 AR017511A1 ARP980104037A AR017511A1 AR 017511 A1 AR017511 A1 AR 017511A1 AR P980104037 A ARP980104037 A AR P980104037A AR 017511 A1 AR017511 A1 AR 017511A1
- Authority
- AR
- Argentina
- Prior art keywords
- lbpb
- polypeptides
- cells
- produce
- neisseria meningitidis
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se trata de polinucleotidos y de polipéptidos de LbpB inclusive, método para producir dichos polipéptidos mediante técnicas recombinantes. También, serevelan métodos para utilizar polipéptidos de LbpB y polinucleotidos en el diseno de protocolos parael tratamiento de enfermedades Neisseriales, entreotras, y los ensayos de diagnostico para tales afecciones. Dichos polinucleotidos codifican los polipéptidos LbpB de Neisseria Meningitidis. Uno delos polinucleotidos corresponde a la secuencia que va del nucleotido 100 al 2274 (SEQ ID N* 1 y respectivamente a las secuencias SEC ID N* 3, 5, 7 y 9).También, se proponen: células transformadas por las secuencias SEC ID. N* 3, o al menos en un rango del orden del 65% por las secuencias mencionadas paraproducir polipéptidos LbpB; un procedimiento para producir dichos polipéptidos LbpB y los polipéptidos obtenidos y también métodos para: identificarcompuestos que inhiben los polipéptidos LbpB; vacunas formuladas con dichos polipéptidos y métodosde vacunacion y de diagnostico que comprenden dichospolipéptidos y composiciones farmacéuticas formuladas con anticuerpos dirigidos contra los polipéptidos mencionados y los equipos de diagnostico que losincluyen.These are polynucleotides and LbpB polypeptides inclusive, a method to produce said polypeptides by recombinant techniques. Also, methods for using LbpB polypeptides and polynucleotides are disclosed in the design of protocols for the treatment of Neisserial diseases, among others, and diagnostic tests for such conditions. Such polynucleotides encode the LbpB polypeptides of Neisseria Meningitidis. One of the polynucleotides corresponds to the sequence from nucleotide 100 to 2274 (SEQ ID N * 1 and respectively to sequences SEQ ID N * 3, 5, 7 and 9). Also, they are proposed: cells transformed by sequences SEQ ID . N * 3, or at least in a range of about 65% by the aforementioned sequences to produce LbpB polypeptides; a method for producing said LbpB polypeptides and the polypeptides obtained and also methods for: identifying compounds that inhibit LbpB polypeptides; vaccines formulated with said polypeptides and vaccination and diagnostic methods comprising said polypeptides and pharmaceutical compositions formulated with antibodies directed against the mentioned polypeptides and the diagnostic equipment that includes them.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9802544.8A GB9802544D0 (en) | 1998-02-05 | 1998-02-05 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017511A1 true AR017511A1 (en) | 2001-09-12 |
Family
ID=10826562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104037 AR017511A1 (en) | 1998-02-05 | 1998-08-14 | ISOLATED POLINUCLEOTIDES THAT CODIFY LBPB OF NEISSERIA MENINGITIDIS, GUEST CELLS TRANSFORMED WITH RECOMBINANT EXPRESSION SYSTEM CAPAZDE TO PRODUCE LBPB POLYPEPTIDE IN BONES CELLS, SUCH CELLULES, BODY CELLS, BIRTHDAYS, BODIES |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR017511A1 (en) |
| GB (1) | GB9802544D0 (en) |
| HU (1) | HUP0002511A3 (en) |
-
1998
- 1998-02-05 GB GBGB9802544.8A patent/GB9802544D0/en not_active Ceased
- 1998-08-10 HU HU0002511A patent/HUP0002511A3/en unknown
- 1998-08-14 AR ARP980104037 patent/AR017511A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0002511A3 (en) | 2004-10-28 |
| HUP0002511A2 (en) | 2000-11-28 |
| GB9802544D0 (en) | 1998-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210269506A1 (en) | Polynucleotides encoding immune modulating polypeptides | |
| US9907837B2 (en) | Composition for preventing or treating cachexia | |
| KR970700438A (en) | MACROPHAGE INFLAMMATORY PROTEINS -3, -4 AND -1sg (g) | |
| AR241654A1 (en) | Human tissue plasminogen activator, pharmaceutical compositions containing it, processes for making it, and dna and transformed cell intermediates therefor | |
| BRPI0109494B8 (en) | factor viii mutein, DNA sequence, vector, process for producing factor viii mutein, pharmaceutical composition and use of factor viii mutein | |
| BR9712348A (en) | isolated polynucleotide molecule, expression vector, cultured cell into which an expression vector was introduced, process to produce an isolated fgf homologous polypeptide, isolated fgf homologous polypeptide, pharmaceutical composition, antibody, processes to stimulate ex vivo myocyte progenitor cells, and, paralyzing an agent or drug selectively for heart tissue. | |
| BRPI0412799A (en) | immunogen, composition, nucleic acid, recombinant cell, methods for preparing a polypeptide, for inducing a protective immune response in a patient and for inducing an anamnesic response in a patient, and optimized yeast nucleic acid sequence | |
| HRP20100370T1 (en) | Chimeric recombinant antigens of toxoplasma gondii | |
| CN1962865A (en) | Human SFRP1 gene, its coded protein and application | |
| CN107530400A (en) | The method for the illness for destroying or removing cell is needed using the peptide treatment from NF-M | |
| KR20100017494A (en) | Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide | |
| EP3862018A1 (en) | Disease treatment drug based on mesenchymal-stem-cell mobilization | |
| CA2404479A1 (en) | Hybrid cytokine of il-7 and .beta.-chain of hepatocyte growth factor | |
| BR112022011975A2 (en) | MODIFIED INTERFERON-2 POLYPEPTIDE, MODIFIED GMOP-INTERFERON-2 POLYPEPTIDE, NUCLEIC ACID, PLASMID, VECTOR, CELL LINE, METHOD FOR PURIFICATION OF MODIFIED INTERFERON-2 POLYPEPTIDE, PHARMACEUTICAL COMPOSITION, METHOD FOR USE OF ONE OR MORE OF MODIFIED INTERFERON-¿2 POLYPEPTIDES AND METHOD TO TREAT A MEDICAL CONDITION IN AN INDIVIDUAL | |
| PT1417231E (en) | Modified human thymic stromal lymphopoietin | |
| Poulter et al. | Levitide, a neurohormone-like peptide from the skin of Xenopus laevis. Peptide and peptide precursor cDNA sequences. | |
| JPH05501500A (en) | TGF-β biosynthetic construct | |
| DE69831084T2 (en) | Beta-defensins | |
| AR017511A1 (en) | ISOLATED POLINUCLEOTIDES THAT CODIFY LBPB OF NEISSERIA MENINGITIDIS, GUEST CELLS TRANSFORMED WITH RECOMBINANT EXPRESSION SYSTEM CAPAZDE TO PRODUCE LBPB POLYPEPTIDE IN BONES CELLS, SUCH CELLULES, BODY CELLS, BIRTHDAYS, BODIES | |
| KR102211959B1 (en) | Composition for preventing or treating metabolic bone disease comprising DUSP5 as active ingredients | |
| KR19990022716A (en) | Bone stimulating factor | |
| EP3811983B1 (en) | Composition for cell transplant, and method for cell transplant | |
| JPH0257192A (en) | Production of motilin-like polypeptide, recombinant dna and plasmid for manifestation for producing same polypeptide | |
| DE60120187T2 (en) | SHORTEN BARD1 PROTEIN AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | |
| CA2743116A1 (en) | Alpha-conotoxin peptides with a 4/7 motif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |